The combination of specific gene targeting technologies mediated transduction of either HER-2/neu-or PTNwith efficient gene delivery systems could provide the targeted ribozymes depleted the respective RNAs and means to evaluate the concept of anticancer strategies inhibited protein expression significantly in three different designed to block expression of potentially rate-limiting human cancer cell lines. This resulted in almost complete tumor promoting factors. Here, we constructed adenoabrogation of HER-2/neu-or PTN-dependent cancer-cell viruses expressing hammerhead-ribozymes targeted to proliferation, thus demonstrating the feasibility of this two of these factors, the tyrosine kinase receptor HERapproach as a future cancer gene therapy. 2/neu or the growth factor pleiotrophin (PTN). Adenovirus-
Introduction angiogenic factors which are rate-limiting in in vivo
Tumor growth and ultimately metastasis is a complex tumor models. The importance of one of these, vascular process regulated in part by factors controlling cellular endothelial growth factor/vascular permeability factor proliferation and death, as well as tumor angiogenesis. [1] [2] [3] (VEGF/VPF), was demonstrated through functional One of these factors, HER-2/neu, a member of the epiknockout through use of blocking antibodies. 12 A critical dermal growth factor (EGF) tyrosine kinase receptor famrole for the other factor, pleiotrophin (PTN), was shown ily has been implicated in mediating growth factor sigin angiogenesis and metastasis associated with melanals, 4, 5 as well as in modulating hormone responsiveness noma using a hammerhead-ribozyme PTN mRNA of breast cancer cells. 6 HER-2/neu is frequently overexdepletion strategy. 13 pressed in a variety of adenocarcinomas including those The availability of ribozyme gene transfer technologies of lung, breast and ovarian cancer. In these tumors, HERto biologically down-regulate expression of specific genes 2/neu overexpression serves as a marker of faster tumor coupled with efficient gene delivery vehicles provides the progression and poor prognosis. [7] [8] [9] Currently, targeting means to evaluate the concept of anticancer strategies to of HER-2/neu expression with anti-HER-2/neu antiblock expression of potentially rate-limiting tumor probodies is being evaluated as a potential therapeutic moting factors such as HER-2/neu or PTN. Hammerapproach in breast cancer patients. Despite a useful role head-ribozymes can be targeted to destroy specific as a diagnostic marker for disease progression, it remains mRNA transcripts by binding to and cleaving specific unclear if HER-2/neu expression is mostly a marker or ribonucleotide sequences, which offers a potential over a rate-limiting factor in cancer cell growth.
other antisense-based technologies. 14 Such ribozymes tarTumor angiogenesis, a process whereby factors stimulgeted to specific oncogenes have been used successfully ating the ingrowth of blood vessels into the tumor are to down-regulate oncogene expression in both in vitro secreted into the local tumor milieu by cancer and stroma and in vivo models. [15] [16] [17] [18] [19] To deliver ribozyme expression cells, also plays a critical role in regulating the balance constructs efficiently into tumor cells in vivo, adenovirus between cell proliferation and cell death and by providvectors seem well suited as an alternative to plasmiding a route for distant spread. 3 Both clinical and laborabased gene transfer technologies. Adenovirus vectors tory evidence suggests that spread of malignant cells provide highly efficient gene transfer and expression in from a localized tumor is directly related to the number vitro and in vivo, can be easily produced in high titers of microvessels in the primary tumor. 10 Of the multitude and have a broad host range. Furthermore, adenovirus of factors secreted by tumor and stroma cells which are vectors have been used for the efficient delivery and expression of ribozymes into tumor cells in culture anticancer strategy. Adenoviruses expressing a hammer-(unpublished data). The PTN ribozyme (RzPTN) cleaves head ribozyme for either HER-2/neu or PTN were conthe PTN mRNA 66 nt downstream of the translation structed and evaluated in four separate human cancer initiation site and contains PTN-specific antisense flankcell lines. Each vector led to high-level gene transfer and ing regions of 12 nt and 11 nt at the 5′ and 3′ ends, hammerhead ribozyme expression and to significant respectively. The specificity and efficacy of the RzPTN depletion of the respective gene products. Importantly, construct was previously demonstrated in in vitro cleavinhibition of either HER-2/neu or PTN gene expression age assays, 22 in transient cotransfection studies in SW-13 in tumor cells abrogated the proliferative effects of these cells, 22 in two human melanoma cell lines stably expressproteins, thus demonstrating the feasibility of these ing the ribozyme in cell culture, 13, 22 and finally, in in vivo therapeutic approaches.
experiments in nude mice. 13 In addition, we used two recombinant adenoviruses expressing either ␤-galactosidase (Av1LacZ4) or luciferase (Av1Luc) as controls in Results some of the experiments.
Recombinant adenoviruses expressing ribozymes were Recombinant adenovirus-mediated ribozyme expression generated by a homologous recombination method. 23 in human cancer cells They were plaque-purified, amplified and titrated in 293 The overall structure of the recombinant adenovirus used cells as described under Materials and methods. Correct in these experiments is depicted in Figure 1a . Ribozyme transgene integration and genomic organization of the expressing vectors were derived from Ad-dl327 by homrecombinant adenoviruses was confirmed by Southern ologous recombination as described in the Materials and analysis (data not shown). A PCR assay for E1a with a methods. The deletion within the E1-region resulted in a sensitivity to detect contaminations of one copy of wildreplication-defective virus and further deletion of the E3 type adenovirus in 10 7 copies of recombinant adenovirus gene region provided space for the incorporation of was used to assure the absence of replication competent transgenes. Ribozymes are expressed under the control wild-type adenovirus (data not shown). of a viral CMV promoter and contain a SV40 polyadenylIn a first set of experiments we compared the levels of ation signal to enable processing and increase transcript ribozyme expression in human cancer cells after adenovistability in eukaryotic cells. The HER-2/neu ribozyme ral infection to expression levels from plasmid-expression (RzHER) targets the HER-2/neu mRNA 1991 nucleotides vectors stably transfected into the same cell lines. Human (nt) downstream of the translation initiation site. HER-SW-13 adrenal carcinoma cells, human 1205 melanoma 2/neu-specific antisense flanking regions of 9 nt and 8 nt and human U87 glioblastoma cells were infected with on the 5′ and 3′ ends of the ribozyme were positioned either Av-RzPTN or Av-RzHER at MOI of 100 and total around a minimized catalytic hammerhead ribozyme RNA was harvested 1 and 3 days after the infection. core of 22 nt, a sequence which we have used successfully Northern analysis revealed very high expression levels in previous studies. 22 The sequence of the target region of both ribozymes in SW-13 and U87 cells (Figure 2a ). and its relative position in the HER-2/neu mRNA are Ribozyme expression was easily detectable after 1 day shown in Figure 1b . The specificity of this HER-2/neu and increased significantly after 3 days. The 50 nt differribozyme construct was demonstrated in in vitro cleavage ence in transcript size between the PTN and HERassays as well as in transient cotransfection studies in ribozymes is due to a slightly modified cloning pro-NIH/3T3 cells using the pRc/CMV plasmid as a cedure. Both ribozymes were also expressed in 1205 ribozyme expression vector. A catalytically inactive melanoma cells although at somewhat lower levels. This mutant ribozyme and an unspecific ribozyme were used as controls in those experiments and had no effects was in stark contrast to the expression levels in SW-13 and significant depletion of HER-2/neu mRNA by approximately 75% 1 day after the infection when compared with the Av-RzPTN control infection. In order to evaluate further the specificity and efficacy of the Av-RzHER vector, human MDA-MB-361 breast cancer cells were infected with Av-RzHER and Av1LacZ4 as control at MOI of 100. HER-2/neu protein levels were determined by FACS analysis over a period of 7 days after adenoviral infection and the mean fluorescence intensities are shown in Figure 3b . Infection with AvRzHER led to a significant reduction of HER-2/neu protein expression compared to the control virus that had no effect on HER-2/neu levels throughout the entire experiment. HER-2/neu levels were reduced 3 days after the levels started to increase again. This time course cor-
13), human melanoma cells (1205) and human glioblastoma cells (U87)
related with the ribozyme expression levels described were infected with Av-RzHER or Av-RzPTN at an MOI of 100. Total above.
RNA was harvested 1 and 3 days after the infection and 20 g were
In the next experiment, we addressed the biological ation in tissue culture. 24 We obtained 32D cells which been stably transfected with PTN ribozyme expression plasmids. The Northern blot was exposed to film for 3 days.
were stably transfected with HER-2/neu and HER-3 expression plasmids (32D/H2+3). In contrast to the parental cell line, these cells survive in the absence of IL-3 when recombinant heregulin, the ligand for HER-3, is and 1205 cells stably transfected with RzPTN expression plasmids. Ribozyme transcripts could not be detected in added to the media. Since only the HER-2/neu/HER-3 heterodimer becomes an active signal transducing recep-1205 cells and only at very low levels in SW-13 cells in a Northern blot that was exposed to film for 3 days (Figure tor upon ligand binding, 25 we speculated that downregulation of HER-2/neu would abrogate the heregulin2c; versus 6 h in Figure 2a) .
In a more detailed time course experiment in human mediated cell survival in these cells. To test this hypothesis 32D/H2+3 cells were infected with either Av-RzHER MDA-MB-361 breast cancer cells, ribozyme expression peaked 3 days after adenoviral infection, decreased rapor Av1LacZ4 and cell survival was compared with uninfected control cells. As expected, withdrawal of IL-3 led idly after day 5 and was not detectable by Northern analysis after day 10 (data not shown).
to almost complete cell death in control and infected cells (Figure 3c , lanes 4-6), whereas the cells proliferated at In order to evaluate the influence of different MOI on ribozyme expression, we examined RzHER levels in comparable levels in the presence of IL-3 (lanes 1-3). Heregulin promoted cell survival in the absence of IL-3 in human SK-OV-3 ovarian cancer cells 3 days after the infection with Av-RzHER at an MOI from 100 to 500. As approximately 40% of the noninfected (lane 7) and Av1LacZ4 control cells (lane 8). In contrast, heregulin shown in Figure 2b , an increase in the MOI from 100 to 500 was followed by a linear, approximately five-fold was not sufficient to prevent cell death significantly in the Av-RzHER infected cells (lane 9). These results increase in RzHER expression. To determine the optimum nontoxic MOI for the subsequent experiments we proved that the HER-2/neu ribozymes were effective in ablating the heregulin-induced cell survival. Furtherinfected the cell lines with the ␤-galactosidase expressing Av1LacZ4 at different MOI and stained for ␤-galactomore, they showed that only the HER-2/neu/HER-3 heterodimeric complex mediates heregulin signal transducsidase expression 48 h after the infection (data not shown). Since in all cell lines 100% of the cells stained tion, and that HER-2/neu is the limiting factor for the mitogenic response in these cells. positive at a nontoxic MOI of 100, this virus titer was used in the following experiments, unless indicated otherwise.
Efficacy of adenovirus-mediated PTN ribozyme expression The specificity and efficacy of this particular PTN Adenovirus-mediated transduction of HER-2/neu ribozymes down-regulates HER-2/neu expression and ribozyme was characterized earlier at the mRNA and protein level in various cell lines in vitro and in vivo.
13,22
inhibits HER-2/neu-mediated proliferation To examine whether a transient adenovirus-mediated Here, we directly assessed the efficacy of adenovirusmediated transduction of PTN ribozymes in a bioassay. transduction of HER-2/neu ribozymes was sufficient to inhibit HER-2/neu expression in cancer cells, we infected
As a model we used SW-13/PTN human adrenal carcinoma cells, which were stably transfected with a PTN SK-OV-3 cells with Av-RzHER or Av-RzPTN as control virus at MOI of 100. Total RNA was harvested 1 and 3 expression plasmid. 26 In contrast to parental SW-13 cells, which do not express PTN endogenously and are not days after the infection and HER-2/neu mRNA levels were quantified by Northern analysis (Figure 3a) . The clonogenic in soft agar, SW-13/PTN cells form colonies spontaneously at a high rate. 26 Consequently, depletion Av-RzHER-specific ribozyme infection led to a specific 
(b) Human breast cancer cells (MDA-MB-361) were infected with Av-RzHER or Av1LacZ4 at an MOI of 100 and HER-2/neu levels were measured by FACS analysis at days 0, 1, 3, 5 and 7. (c) Mouse hematopoietic stem cells (32D/H2+3) which had been stably transfected with expression plasmids for human HER-2/neu and HER-3 receptors were infected with Av-RzHER or Av1LacZ4 at an MOI of 100. Noninfected cells served as an additional negative control. Cells were grown in the presence of interleukin-3 (IL-3; lanes 1-3), without IL-3 (lanes 4-6) or in the presence of heregulin at 10
−9 m without IL-3 (lanes 7-9) and counted manually.
of PTN expression by adenovirus-mediated ribozyme targeting should reverse colony formation in these cells. SW13/PTN cells were infected with Av-RzPTN or AV1LacZ4 at an MOI from 1 to 100, plated in soft agar and colony formation was measured after a 10-day incubation period. Av-RzPTN infection at an MOI of 25 led to a dramatic reduction in colony formation by Ͼ85% compared with the control infection (Figure 4 ).
Discussion
The significance of angiogenic factors for the growth and metastasis of solid tumors has gained wide acceptance. 3 Using ribozyme targeting, we recently demonstrated that pleiotrophin is a limiting factor in melanoma angiogenesis and metastasis. 13 HER-2/neu overexpression is com- a plasmid-based ribozyme targeting strategy and success-fully depleted HER-2/neu levels in ovarian cancer cells, 2/neu and PTN substrate mRNAs are expressed at very high levels in these cell lines. which reversed tumorigenesis in these cells (unpublished A recently published study found that ribozymes tardata). These results suggested that ribozyme targeting geted against human growth hormone had significant can potentially be used to achieve two important goals: effects after adenovirus-mediated transduction in vivo in (1) as diagnostic tools to elucidate the relevance of a gene mice, and that the time course of ribozyme expression product; and (2) as new adjuvant reagents in human canwas correlated with the inhibition of hGH expression in cer gene therapy. the liver. 21 On the other hand, we have recently obtained In order to develop an anticancer gene therapy with data from plasmid-based vectors suggesting that ribozymes targeted against either HER-2/neu or PTN we ribozyme expression levels do not correlate very well needed to generate an efficient gene delivery vector. To with their efficacy (unpublished data). It seems possible that end, we selected adenovirus, which has been extenthat other factors, such as target selection or ribozyme sively used to obtain high levels of transduction and gene design and expression in the proper cellular expression in cultured cells and animals. 27, 28 compartment(s) have a much greater influence on their In this study, we combined ribozyme gene-targeting efficacy than ribozyme expression levels. These results technology with adenovirus-mediated gene delivery and could potentially be important if sufficient ribozyme levwere able to demonstrate a specific and efficacious downels can be achieved at lower virus titers which in turn regulation of HER-2/neu and PTN in a variety of human would reduce nonspecific viral toxicity in normal cells. cancer cells. We used our previously reported PTN One of the potential problems of a replication-defective hammerhead-ribozyme design and applied that to generadenovirus vector is the transient transgene expression. ate ribozymes targeted to the HER-2/neu mRNA. The
Figure 4 Av-RzPTN infection reduces growth of SW-13/PTN cells in
In rapidly proliferating MDA-MB-361 cells ribozymeconstruction and testing of those plasmid-based mediated inhibition of HER-2/neu protein expression expression vectors will be described in detail elsewhere.
started to decrease 5 to 7 days after the infection (see FigOne of the disadvantages of our plasmid-based ure 3b). This transient expression would mandate a need expression vectors is low ribozyme transcript levels. We for repetitive virus administrations, which is problematic were unable to detect ribozyme transcripts by quantitatdue to the strong immunogenicity of the currently availive methods such as Northern analysis or ribonuclease able adenovirus vectors. On the other hand, a transient protection assays after transient or stable transfections.
but very efficient depletion of crucial rate-limiting gene Thus it was impossible to correlate effects (or the lack products such as demonstrated here (see Figures 3c and thereof) to ribozyme expression levels. Fortunately, this 4), could already be sufficient to alter the balance does not appear to be the case when the adenovirus sysbetween cell proliferation and cell death and could tem was used. Adenovirus-mediated transduction proinitiate tumor regression in vivo. duced high steady-state levels of ribozyme expression in Poor tissue penetration is one of the major obstacles in four different human cancer cell lines (see Figure 2 ). This using replication-deficient adenovirus vectors in cancer increase in ribozyme production is most likely due to the gene therapy. Successful approaches rely on the develophigher copy number of template using adenovirus as ment of in vivo tumor models, which either allow tarcompared with stably integrated plamid-derived trangeting of a high percentage of the tumor cells, or show scription units, since the same ribozyme expression casefficacy already at low transduction rates. In two such sette (promoter and transcription unit) was used. The fact models replication-deficient adenovirus vectors have that we observed a viral dose-dependent inhibition of been used successfully to inhibit the intracranial growth soft agar colony formation in SW13/PTN cells (see Figure  of experimental gliomas, 29 as well as the intraperitoneal 4) suggests a correlation between ribozyme expression growth of human lung cancer cells in nude mice. 30 levels and effects. The differences in expression in differWe recently reported that the expression of pleiotroent cell lines are probably due to different CMV-prophin is rate-limiting for the in vivo growth and metastasis moter activities in the cell lines, since control infections of human melanoma cells. 13 Furthermore, our data indiwith a ␤-gal expressing virus had demonstrated, that at cated that targeting as few as 25% of all tumor cells was an MOI of 100, all cells were infected and expressed simialready sufficient to significantly delay tumor growth. lar levels of ␤-galactosidase activity (data not shown).
These findings provide the experimental basis for an Adenovirus-mediated transduction of either HERattractive in vivo model to test the antitumor/ antimeta-2/neu or PTN ribozymes yielded not only high static efficacy of the Av-RzPTN ribozyme expressing expression levels but also led to a specific and very vectors. efficient depletion of the respective gene products in two
In conclusion, our results demonstrate that adenovirusdifferent cell lines (see Figure 3a and b) . Although the mediated ribozyme expression is a very efficient tool to contribution of antisense effects can not be completely abrogate the expression of oncogenes and growth factors ruled out, it seems likely that ribozyme-mediated cleavin cancer cells. The efficacy of these adenoviruses in in age of the target RNA is the main mode of action, since vivo tumor models remains to be evaluated. plasmid-delivered catalytically inactive mutant ribozymes had no effects on protein expression. 22 In SK-
Materials and methods
OV-3 cells, HER-2/neu mRNA levels were reduced by approximately 75% only 1 day after the infection. This suggests that low ribozyme levels can be sufficient to Cell culture, viruses and plasmids obtain maximal effects, taking into consideration that the Human adrenal carcinoma (SW-13), glioblastoma (U87), peak of ribozyme expression occurs around 3 days after ovarian cancer (SK-OV-3) and embryonic kidney epithe infection. In addition, the ribozyme effects may have thelial (293) Technologies) various MOI in infection medium (IMEM plus 2% FBS) for 2 h with rocking. After that, infection medium was mixed at a ratio of 3:1 and supplemented with 5% FBS. 32D mouse hematopoietic stem cells which were stably replaced with normal growth medium and cells were used in the experiments as indicated. cotransfected with HER-2/neu and HER-3 expression plasmids (32D/H2+3; gift from J Pierce, NCI, NIH, Rockville, MD, USA) were grown in IMEM with 10% FBS.
Northern analysis Total cellular RNA was isolated with the RNA STAT-60 Recombinant adenoviruses expressing either ␤-galactosidase (Av1LacZ4) or luciferase (Av1Luc) as well as Admethod (Tel-Test, Friedenswood, TX, USA), separated and blotted as described. 26 A HER-2/neu cDNA probe dl327 virus DNA and PAVS6A plasmid DNA which were used for the subsequent adenovirus (Av)-vector construc-(1.5 kb EcoRI fragment) was hybridized, washed and exposed to film for 16 h. 26 To correct for variability in tions were described earlier. 27, 31 loading, blots were stripped and reprobed with a glyceraldehyde-3 phosphate dehydrogenase (G3PDH; Clontech, Palo Alto, CA, USA) cDNA probe. Relative band Construction of recombinant adenoviral vectors In order to generate a recombinant adenovirus that intensities were measured by densitometry. PTN or HER-2/neu ribozyme transcripts were detected with ␥-32 P-T4-expressed hammerhead-ribozymes (Rz) targeted to pleiotrophin (PTN), we used the Rz minigene expression caskinase labeled oligonucleotides (45 nt long) as probes. Hybridization and washing conditions were modified as sette from the pRc/CMV-Rz66 expression plasmid. 22 The expression cassette was cut out as a NruI-XbaI fragment follows: the hybridization buffer contained only 25% formamide and the final washing step was done at 50°C, (826 nucleotides (nt)) and blunt-end ligated into the EcoRV side of the PAVS6A Av-shuttle plasmid. The gen-0.5 × SSC/0.1% SDS for 30 min. eration of the eukaryotic expression plasmid that contains the Ribozyme targeted to HER-2/neu will be as negative controls. Recombinant replication-deficient adenoviral vectors were constructed by a homologous recombination Growth assays SW-13/PTN cells 26 were infected with Av-RzPTN or Avmethod 23 using PAVS6A-Rz shuttle plasmids and the 35 kb ClaI fragment of Ad-dl327. 293 Cells were cotransRzHER at MOI of 100 for 2 h. Infected cells were then trypsinized and 2 × 10 4 cells were plated in 35 mm soft fected with the respective PAVS6A plasmid and virus DNA and individual plaques containing recombinant agar dishes in triplicates. Soft agar colony formation was evaluated after a 10-day incubation period as described virus were purified and further amplified in 293 cells as described. 31 Recombinant adenoviral DNA was analyzed previously. 26 32D cell proliferation/survival assay was performed as reported. 32 In brief, 32D/H2+3 cells were by restriction enzyme digestions with EcoRI, NdeI and XbaI followed by Southern analysis using radiolabeled plated overnight at 50-70% confluence in 12-well plates and then infected with Av-RzHER or Av1LacZ4 at MOI oligonucleotides specific for RzPTN or RzHER as probes. Adenoviruses with the correct restriction pattern were of 100 for 2 h. Infected or noninfected cells were then grown for 48 h in the absence or presence of interleukinproduced in large amounts and purified in a two-step CsCl ultracentrifugation procedure.
31 Viral titers were 3, or in the presence of recombinant heregulin (Neomarkers) at 10 −9 m without addition of IL-3. Proliferobtained by plaque forming assays in 293 cells and high titer virus stocks were divided into aliquots and stored ation was then assessed by counting surviving cells manually using a hemocytometer. at −80°C.
31 To rule out minor contaminations with replication-competent wild-type adenovirus, PCR reactions with E1-specific primer pairs were performed using 1 g
